Overview
Orilissa (elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis.

Coverage Guidelines
Members will be granted approval of Orilissa when ALL the following criteria have been met and documentation has been submitted:
1. Member has OB/BYN documented diagnosis of endometriosis with moderate to severe pain
2. Member is 18 years of age or older
3. Member has had an insufficient response or intolerance to generic alternatives in at least two of the following therapeutic drug classes:
   - Nonsteroidal anti-inflammatory drugs (NSAIDs)
   - Hormonal contraceptives
   - Oral or depot medroxyprogesterone
4. Member has had an inadequate response, adverse reaction, or contraindication to Lupron

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition.

Limitations
- Initial approvals will be granted for the following:
  - Endometriosis without dyspareunia (150mg tablets) – 6 months
  - Endometriosis with dyspareunia (200mg tablets) – 6 months (maximum)
- Reauthorization will be granted for the following:
  - Endometriosis without dyspareunia (150mg tablets) – 6 months
Endometriosis with dyspareunia (200mg tablets) – Maximum of 6 months
- Reauthorizations of Orilissa 200mg for the treatment of moderate to severe pain associated with endometriosis with dyspareunia will not be granted.

References
1. Orilissa (elagolix) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2018.

Review History
02/20/19 – Reviewed

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.